FDA ap­proves San­doz’s na­tal­izum­ab biosim­i­lar, like­ly putting a damper on Bio­gen’s Tysabri sales

On the back of San­doz’s FDA ap­proval for the first-ever na­tal­izum­ab biosim­i­lar, brand­ed as Tyruko, Bio­gen now has a for­mi­da­ble mul­ti­ple scle­ro­sis mar­ket com­peti­tor for its top-sell­ing mon­o­clon­al an­ti­body Tysabri.

“Tyruko has the po­ten­tial to ex­tend the reach of na­tal­izum­ab treat­ment for these pa­tients, in­crease health­care sav­ings and fu­el in­no­va­tion through com­pe­ti­tion in the mar­ket,” San­doz North Amer­i­ca pres­i­dent Keren Haru­vi said in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER